ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
45
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,466
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3 and VEGF through disruption of HER/MET crosstalk
Author(s):
S Hu
,
W Fu
,
W Xu
,
J Takamizawa
,
H Konishi
,
K Yanagisawa
,
S Tomida
,
H Osada
,
H Endoh
Publication date:
2014
Journal:
Cancer Res.
Read this article at
ScienceOpen
Publisher
PubMed
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Journal of the ASEAN Federation of Endocrine Societies
Author and article information
Journal
DOI::
10.1158/0008-5472
PubMed ID::
15172979
ScienceOpen disciplines:
Endocrinology & Diabetes
,
Medicine
,
Uncategorized
Data availability:
ScienceOpen disciplines:
Endocrinology & Diabetes
,
Medicine
,
Uncategorized
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,466
The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer
Authors:
K Yonesaka
,
H Kawakami
,
H. Kaneda
Abstract 2358: miRNA-483-3p overexpression unleashes invasiveness of metastatic colorectal cancer by NDRG1 targeting and upregulation of the HER3-AKT axis
Authors:
Ermes Candiello
,
Gigliola Reato
,
Federica Verginelli
…
202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
Authors:
M. Oliveira
,
J.M. Cejalvo Andujar
,
M. Margeli Vila
…
See all similar
Cited by
3
MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells
Authors:
Weibin Wang
,
Lijun Zhao
,
Xueju Wei
…
Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
Authors:
Maria Prat
,
Francesca Oltolina
,
Cristina Basilico
MicroRNAs: nova classe de reguladores gênicos envolvidos na função endócrina e câncer
Authors:
Júlio Ricarte Filho
,
Edna Kimura
See all cited by